Facebook
Twitter
LinkedIn
ForwardHPV Negative HNSCC: Understanding Biology and the Path to Progress
There is a great need for improvement in outcomes for HPV negative HNSCC patients. There are ongoing efforts to better understand the biology of HPV negative HNSCC, and reported and ongoing therapeutic clinical trials to try to improve outcomes in this patient population. It is important to be up to date with subject matter in order to best counsel and treat patients as well as plan future research for these patients.
It is imperative that providers and researchers stay up to date with current practice, understanding and future directions in the treatment of HPV negative HNSCC. This session will provide attendees with the opportunity to gain exposure to the current state of knowledge in understanding the biology of this disease and also understand current management and past and future trials.
Participants need to determine when and how the latest science and clinical data will affect their day-to-day practice, and thus be able to narrow competency gaps in the understanding of HPV negative HNSCC.
There is a great need for improvement in outcomes for HPV negative HNSCC patients. In this session we will first discuss our current understanding of the biology and tumor immune microenvironment in HPV negative HNSCC, critically important to improving therapeutic efficacy. Subsequently, the talks will be focused on our current management and therapeutic options as well as the latest clinical trials and future directions in the treatment of HPV negative HNSCC, in both the curative intent and recurrent/metastatic setting.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the biology and tumor immune microenvironment in HPV negative HNSCC patents.
- Identify current treatment options and future directions in the treatment of HPV negative HNSCC in the curative intent setting.
- Identify current treatment options and future directions in the treatment of HPV negative HNSCC in the recurrent/metastatic setting.
Dan Zandberg, MD, is employed by the University of Pittsburgh Medical Center and has no financial relationships with a commercial interest.
Christine Chung, MD, is employed by H. Lee Moffitt Cancer Center and is a consultant with AVEO, Exelixis, Fulgent, Genmab and Seagen.
Andrew Sikora, MD, PhD, is employed by the Baylor College of Medicine and has no financial relationships with a commercial interest.
Doug Adkins, MD, FACP, is employed by the Washington University School of Medicine and receives research/consultant compensation from Boehringer-Ingelheim, Cue, Eisai, EMD Serano, Genmab, Immunitas, Inhibrix, Kura, Merck, Merck KGaA, Purple Biotech and Seagen. He also serves in a leadership position with Barnes Jewish Hospital.
Nabil Saba, MD, FACP, is employed by Emory University. He serves on the advisory board and/or receives research or honoraria compensation from Aduro, AZ, Eisai, Exelixis, Merck, EMD Serono, AstraZeneca, Bionteck, TOSK, BMS, Celldex, Surface Onc, Astex, Immugene, Faron, Coherus, Adegene, Fulgent, Nanobiotix, Flamingo, Infinity, Inovio, Aveo, Cornerstone, Kura, Vaccinex, CUE, GSK, Medscape, Onclive, UptoDate and Springer.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.